Experimental Therapeutics of Cancer

Advancing "personalized medicine" in cancer care by understanding how gene-related processes lead to cancer, and how genetic variation among individuals affects tumor growth and response to treatment.

The Experimental Therapeutics of Cancer Scientific Program focuses on understanding the molecular events leading to individual human cancers and how the molecular differences between tumors influence their behavior and response to therapy. Further, the Program seeks to understand the role of inter-individual genetic variation in developing and treating cancer and to use this information to provide a rationale basis for developing novel diagnostic prevention and therapeutic strategies.

For more information contact the program leader, David Boothman, Ph.D.

Program Themes

  • Identify the genetic and epigenetic abnormalities underlying the pathogenesis of common human malignancies.
  • Determine the frequency and the timing of their onset in pathogenesis.
  • Determine molecular differences between tumors that correlate with important clinical variables (e.g. survival, metastases, response to treatment).
  • Identify inter-individual genetic variation in the development of cancer and response to its treatment.
  • Develop preclinical models to document the functional relevance of the various molecular changes.
  • Develop ways to translate these findings into new methods for the early detection, prevention, imaging, prognosis, and selection for therapy for individual patients.
  • Provide an interface for basic investigators, clinical scientists, and, as appropriate, biotechnology and pharmaceutical companies to develop and perform early stage clinical trials.
  • Provide an interface with other cancer center programs and cores to facilitate these aims.

How To Get Involved

Uptake of peptide-targeted nanoparticles by H2009 non-small-cell lung cancer
Polymeric Micelle Nanoparticles

The Molecular Therapeutics of Cancer Scientific Program seeks additional physicians and scientists with broad understanding of molecular events leading to human cancers for further collaboration research projects.